RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q4 FY24 results · Jan–Mar 2024
RPG Life Sciences reported revenue from operations of ₹126.99 crore (up 7.2% from Q4 FY23) and net profit of ₹13.24 crore (up 27.9% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a standalone basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 126.99 | 118.49 | +7.2% | 153.70 | −17.4% |
| Other income | 1.65 | 1.84 | −10.3% | 1.92 | −14.1% |
| Total income | 128.64 | 120.33 | +6.9% | 155.62 | −17.3% |
| Profit before tax | 17.74 | 13.81 | +28.5% | 35.54 | −50.1% |
| Net profit for the period | 13.24 | 10.35 | +27.9% | 26.46 | −50.0% |
| EPS, basic (₹) | 8.01 | 6.26 | +28.0% | 16.00 | −49.9% |
| Net margin (%) | 10.4 | 8.7 | 17.2 |
Standalone
- Filed with BSE
- 08 May 2024, 15:26 IST
- Board meeting
- 30 Apr 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE